F.D.A. review of Crown Laboratories Inc. continues.LAS VEGAS--(BUSINESS WIRE)--June 7, 1996--Crown Laboratories Inc. (AMEX AMEXSee: American Stock Exchange EC: CLL CLL abbr. chronic lymphocytic leukemia CLL, n.pr See leukemia, chronic lymphocytic. CLL 1. Chronic lymphocytic leukemia 2. Cholesterol-lowering lipid ) reported that its final F.D.A. review process is proceeding according to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. standard F.D.A. review procedures. As anticipated, Crown's manufacturing personnel recently met with the F.D.A. to discuss the company's pending submission. There were requests for some information for clarification purposes. Crown and the National Food Laboratory collaborated on its request and fulfilled ful·fill also ful·fil tr.v. ful·filled, ful·fill·ing, ful·fills also ful·fils 1. To bring into actuality; effect: fulfilled their promises. 2. the follow-up submission on June 5. At this time, Crown is not aware of any outstanding issues and is awaiting the F.D.A.'s response. Matters discussed in this news release contain forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. that involve risks and uncertainties including the time needed to complete any additional information on test results required by the F.D.A. No assurance can be given as to the time ultimately taken by the F.D.A. to complete their review. These and other risks are detailed from time to time in the company's S.E.C. Reports, including Form 10-QSB for the quarter ended March 31, 1996, and Form 10-KSB for the year ended Dec. 31, 1996. CONTACT: Crown Laboratories Lawrence Rosenthal, 610/667-4448 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion